Daily Alpha · X
· Premarket Alpha · by Buzzberg Research
The strongest X evidence was behavioral: a selective NBIS re-entry, a leverage post-mortem, explicit biotech changes and ASE execution detail.
Themes on this desk
Selective re-entry
A fresh NBIS call purchase followed a broad reduction in correlated AI risk.
Packaging bottleneck
ASE demand is strong, but capex and cash conversion keep the equity outcome conditional.
Actual changes
The biotech ledger separates additions and closures from watchlist language.
Ticker heat
?
Top voices by smart followers and alpha score
Market Radar →Bubbleboi re-entered Nebius through $200 calls
Bubbleboi explicitly said he bought NBIS $200-strike calls last Thursday after not being long at the start of the month.
@RasmusK1337 I wasn’t long nebius at start of month and I bought $200 strikes last Thursday
This is a fresh, high-beta re-entry after the speaker had cut broad semiconductor exposure, not generic bullish commentary.
Watch NBIS contract execution and option exposure through the next earnings update.
Source →Cross-book correlation forced a complete long reduction
Bubbleboi said correlations went to one and volatility became abnormal, so he cut every long rather than infer inside information from the tape.
Correlations across my book went to one and vol spiked far past anything normal, so I cut every long and
The episode shows how nominal long-short diversification can fail when both books encode the same AI factor.
Watch Cross-sectional correlation and realized volatility across semis, photonics, SaaS and IT services.
Source →ASE's demand strength carries a heavy cash-conversion burden
The read-through flags $10.5 billion of 2026 capex, persistent negative free cash flow and another large spending year in 2027.
2026 capital expenditure has increased to US$10.5bn, negative free cash flow will persist, 2027 capital expenditure will remain large, and
Strong orders do not automatically translate into near-term equity cash yield for OSATs.
Watch Capex revisions, free-cash-flow conversion and project commissioning against LEAP growth.
Source →Seedy19 added four biotech positions
Seedy19 disclosed increases in ABVX, VERA, NKTR and TENX.
The Weekly 🌱 New: Increased: $abvx , $vera , $nktr , $tenx Unchanged: $iva, $cccc Decreased: Closed:
The post records actual portfolio changes rather than a watchlist or promotional thesis.
Watch NKTR's settlement catalyst, TENX's August event and follow-through in ABVX and VERA.
Source →Lassonde remains a watchlist idea, not a purchase
Myles said LASA.TO is a stock he is close to picking up; he did not claim a current position.
A stock I'm close to picking up is Lassonde $LASA.to.
The distinction prevents a valuation thesis from being mislabeled as disclosed buying.
Watch Completion of the new plant and the expected manufacturing-capacity and cash-flow step-up.
Source →